● Editas Medicine shares have fallen sharply, most recently closing at $2.94, down 9.54%, with no confirmed company-specific catalyst identified, consistent with sector-wide pressure on early-stage gene-editing biotech.
● Edesa Biotech shares have fallen sharply, most recently closing at $4.76, down 17.22%, extending weakness tied to a $25.0 million public offering priced at a combined $5.50 per unit.
● Ginkgo Bioworks shares have fallen sharply, most recently closing at $6.96, down 9.73%, extending a downtrend reinforced by its most recent quarterly report.
● Digital Brands Group shares have fallen sharply, most recently closing at $9.50, down 19.83%, continuing to trade far below the non-binding $77.58-per-share buyout proposal disclosed August 5, 2026.
● Capricor shares have swung wildly, most recently closing at $6.84, down 14.35%, after FDA briefing documents said the Phase 3 HOPE-3 trial missed its pre-specified primary and secondary endpoints, followed by a 9-to-3 negative advisory-committee vote.
● Cato Corporation shares have fallen sharply, most recently closing at $3.04, down 18.93%, a day after reporting a steep drop in quarterly profit.
● Coty shares have fallen sharply, most recently closing at $2.75, down 9.24%, following its fiscal fourth-quarter report.
● CXApp shares have fallen sharply, most recently closing at $3.94, down 14.16%, after a 1-for-50Reverse Stock Splitreduced shares outstanding from roughly 116.9 million to about 2.34 million to supportNasdaqbid-price compliance.
● China Yuchai International shares have fallen sharply, most recently closing at $38.71, down 10.89%, following a sharp year-to-date rally.
● Ameresco shares have fallen sharply, most recently closing at $22.19, down 12.47%, giving back an earlier rally that followed Q2 2026Revenueof $515.5 million, up about 9.1% year over year and nearly 12% above analyst estimates.